A study of a several doses of a novel treatment for chronic itch compared to placebo for
patients whose condition has not responded to other treatments
A study of a several doses of a novel treatment for chronic itch compared to placebo for
patients whose condition has not responded to other treatments
A Randomized Placebo-Controlled Study of the Neurokinin-1 (NK1) Receptor Antagonist Serlopitant Prurigo Nodularis (PN)
Completed
Menlo Therapeutics Inc.
Phase 2
The purpose of this study is to demonstrate whether or not VPD-737, an NK1 receptor
antagonist is safe and effective for treatment of prurigo nodularis versus placebo.
A Randomized Placebo-Controlled Study of the Neurokinin-1 (NK1) Receptor Antagonist Serlopitant Prurigo Nodularis (PN)
Completed
Vyne Therapeutics Inc.
Phase 2
The purpose of this study is to demonstrate whether or not VPD-737, an NK1 receptor
antagonist is safe and effective for treatment of prurigo nodularis versus placebo.
Neurokinin-1 Receptor Antagonist for the Treatment of Itch in EB Patients
Completed
Epidermolysis Bullosa Research Partnership
Phase 2
Our goal is to determine whether daily oral administration of VPD-737 (5 mg) is effective and
safe in treating moderate to severe pruritus in patients with Epidermolysis Bullosa (EB).
Neurokinin-1 Receptor Antagonist for the Treatment of Itch in EB Patients
Completed
Menlo Therapeutics Inc.
Phase 2
Our goal is to determine whether daily oral administration of VPD-737 (5 mg) is effective and
safe in treating moderate to severe pruritus in patients with Epidermolysis Bullosa (EB).
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
